Biogen (BUE:BIIB) Short-Term Debt : ARS210,625 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Biogen Short-Term Debt?

Biogen's Short-Term Debt for the quarter that ended in Mar. 2024 was ARS210,625 Mil.

Biogen's quarterly Short-Term Debt declined from Sep. 2023 (ARS174,975 Mil) to Dec. 2023 (ARS54,150 Mil) but then increased from Dec. 2023 (ARS54,150 Mil) to Mar. 2024 (ARS210,625 Mil).

Biogen's annual Short-Term Debt declined from Dec. 2021 (ARS100,899 Mil) to Dec. 2022 (ARS0 Mil) but then increased from Dec. 2022 (ARS0 Mil) to Dec. 2023 (ARS54,150 Mil).

Biogen Short-Term Debt Historical Data

The historical data trend for Biogen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Short-Term Debt Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

89,409.35

100,899.11

54,150.00

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	174,975.01	54,150.00	210,625.00

Biogen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Biogen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biogen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.